Daiichi Sankyo Company, Limited, a global pharmaceutical company,
announced details of the application for its Take a New Challenge for
Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug
discovery initiative for universities and research institutes in Europe.
The TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers in Germany, Switzerland and Austria, and becoming known as the TaNeDS Global Programme. Now, in 2014, it has expanded further across Europe to include all EU member countries. The program is conducted with the aim of realizing Daiichi Sankyo’s corporate slogan of “Passion for Innovation. Compassion for Patients.” Through increasing collaborative opportunities with researchers in Europe. U3 Pharma GmbH, a wholly owned subsidiary of Daiichi Sankyo, is also participating in the programme in order to nurture the seeds of drug discovery for the next generation.
The TaNeDS Global Programme 2014: Countries where research could be conducted: All EU member countries plus Norway and Switzerland.
Overview of research programmes: Daiichi Sankyo seeks innovative technological research collaborators for novel drug discovery and testing projects that could result in novel drug discovery and novel new drugs.
Research themes: 1) Cancer - New targeted and investigative research for small-molecule and biologic treatments (antibody drugs, etc.). 2) Cardiovascular and metabolic disorders - New mechanisms and drug treatments for obesity, kidney and renovascular-related disorders. 3) Other disorders - New mechanisms and drug treatments for genetic disorders, new drug treatments for pain, genetic analysis and new drug research for rare diseases. 4) Revolutionary drug discovery technology - New biologic technology, target molecules and delivery systems for nucleic acid treatments, new technology for drug development based on protein structural analysis.
The TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers in Germany, Switzerland and Austria, and becoming known as the TaNeDS Global Programme. Now, in 2014, it has expanded further across Europe to include all EU member countries. The program is conducted with the aim of realizing Daiichi Sankyo’s corporate slogan of “Passion for Innovation. Compassion for Patients.” Through increasing collaborative opportunities with researchers in Europe. U3 Pharma GmbH, a wholly owned subsidiary of Daiichi Sankyo, is also participating in the programme in order to nurture the seeds of drug discovery for the next generation.
The TaNeDS Global Programme 2014: Countries where research could be conducted: All EU member countries plus Norway and Switzerland.
Overview of research programmes: Daiichi Sankyo seeks innovative technological research collaborators for novel drug discovery and testing projects that could result in novel drug discovery and novel new drugs.
Research themes: 1) Cancer - New targeted and investigative research for small-molecule and biologic treatments (antibody drugs, etc.). 2) Cardiovascular and metabolic disorders - New mechanisms and drug treatments for obesity, kidney and renovascular-related disorders. 3) Other disorders - New mechanisms and drug treatments for genetic disorders, new drug treatments for pain, genetic analysis and new drug research for rare diseases. 4) Revolutionary drug discovery technology - New biologic technology, target molecules and delivery systems for nucleic acid treatments, new technology for drug development based on protein structural analysis.
No comments:
Post a Comment